Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL C CAMERON

Allopathic & Osteopathic Physicians Dermatology

NPI
1912391186
CMS profile
5706498
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$19,510.57

192 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $13,345.00 6
Food and Beverage $6,165.57 186

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL C CAMERON

NPI 1912391186 · CMS profile ID 5706498

Allopathic & Osteopathic Physicians / Dermatology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912391186?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL C CAMERON, NPI 1912391186, CMS profile ID 5706498. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912391186?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MICHAEL C CAMERON, NPI 1912391186, CMS profile ID 5706498. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912391186?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MICHAEL C CAMERON, NPI 1912391186, CMS profile ID 5706498, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1912391186?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

192 matching records · $19,510.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 192 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 192.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $21.2111/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154844 CMS
AbbVie Inc. $22.5911/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205747 CMS
AbbVie Inc. $2.3011/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205745 CMS
Janssen Biotech, Inc. $71.3811/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788815811 CMS
AbbVie Inc. $6.2211/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205743 CMS
Incyte Corporation $1,720.0011/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835575475 CMS
Journey Medical Corporation $66.2511/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852082947 CMS
PFIZER INC. $22.9311/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833141695 CMS
AbbVie Inc. $19.4611/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205741 CMS
PFIZER INC. $26.5611/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833110875 CMS
PFIZER INC. $12.0711/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833108039 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $86.9811/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851912025 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $13.5211/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851912043 CMS
Lilly USA, LLC $21.4011/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818611773 CMS
AbbVie Inc. $20.2511/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205739 CMS
AbbVie Inc. $48.9711/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205737 CMS
UCB, Inc. $19.8311/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807453393 CMS
Regeneron Healthcare Solutions, Inc. $89.2511/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809563415 CMS
LEO Pharma Inc. $26.2611/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154761 CMS
LEO Pharma Inc. $1.2511/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154777 CMS
Incyte Corporation $20.4011/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853495983 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $15.8811/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851912037 CMS
AbbVie Inc. $1,800.0011/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205735 CMS
AbbVie Inc. $21.0610/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205733 CMS
AbbVie Inc. $7.9010/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205731 CMS
LEO Pharma Inc. $8.0210/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154740 CMS
AbbVie Inc. $20.3310/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205729 CMS
LEO Pharma Inc. $19.3610/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154705 CMS
LEO Pharma Inc. $2.3310/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154725 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.9910/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851912027 CMS
GENZYME CORPORATION $18.2910/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843761293 CMS
Lilly USA, LLC $0.8410/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818604223 CMS
Lilly USA, LLC $12.7910/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818611771 CMS
LEO Pharma Inc. $2.1210/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154671 CMS
LEO Pharma Inc. $3.7510/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154687 CMS
E.R. Squibb & Sons, L.L.C. $23.5610/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783562287 CMS
LEO Pharma Inc. $75.1810/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154637 CMS
LEO Pharma Inc. $18.4810/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842154653 CMS
Journey Medical Corporation $43.3310/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852082945 CMS
Lilly USA, LLC $116.2810/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818662461 CMS
Regeneron Healthcare Solutions, Inc. $39.9010/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809563413 CMS
AbbVie Inc. $25.3910/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794205727 CMS
E.R. Squibb & Sons, L.L.C. $18.6010/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783562299 CMS
E.R. Squibb & Sons, L.L.C. $1,013.0110/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783562301 CMS
Incyte Corporation $49.2210/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835575479 CMS
Regeneron Healthcare Solutions, Inc. $36.4010/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809563411 CMS
UCB, Inc. $123.3510/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807461561 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $20.2510/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849562075 CMS
Incyte Corporation $14.3010/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853495981 CMS
Regeneron Healthcare Solutions, Inc. $19.1710/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809563409 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,242.19 3
PY2020 $38.47 1
PY2021 $19,510.57 192
PY2022 $448,864.86 732
PY2023 $625,522.96 869
PY2024 $808,002.47 953
PY2025 $737,247.17 806

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,083.63 1
PY2025 Principal investigator $2,787,765.84 247
PY2024 Recipient $2,386.50 1
PY2024 Principal investigator $345,695.38 21
PY2022 Recipient $12,400.00 5
PY2021 Recipient $14,220.00 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

248 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202532865
Principal investigator 1 ABBVIE INC. $4,500.00 12/30/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202532214
Principal investigator 1 SANOFI US SERVICES INC. $37,375.00 12/22/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156713
Principal investigator 1 SANOFI US SERVICES INC. $16,798.75 12/22/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156718
Principal investigator 1 SANOFI US SERVICES INC. $5,850.00 12/22/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156722
Principal investigator 1 SANOFI US SERVICES INC. $12,584.52 12/22/2025 Non-covered Recipient Entity
Equity Medical Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226156731
Principal investigator 1 SANOFI US SERVICES INC. $3,511.00 12/22/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156736
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,300.40 12/18/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431887
Principal investigator 1 Incyte Corporation $1,000.00 12/11/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533979
Principal investigator 1 Incyte Corporation $1,300.00 12/11/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533983
Principal investigator 1 Incyte Corporation $1,300.00 12/11/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533988
Principal investigator 1 Incyte Corporation $405.00 12/11/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240534002
Principal investigator 1 Incyte Corporation $8,750.00 12/11/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240534005
Principal investigator 1 ABBVIE INC. $1,200.00 12/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202529634
Principal investigator 1 SANOFI US SERVICES INC. $3,960.77 12/08/2025 Non-covered Recipient Entity
University Of New Mexico
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226125198
Principal investigator 1 SANOFI US SERVICES INC. $23,836.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156638
Principal investigator 1 SANOFI US SERVICES INC. $2,006.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156662
Principal investigator 1 SANOFI US SERVICES INC. $33,891.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156669
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226156677
Principal investigator 1 SANOFI US SERVICES INC. $2,537.00 12/08/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156679
Principal investigator 1 ABBVIE INC. $1,500.00 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202528316
Principal investigator 1 ABBVIE INC. $5,496.00 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202528318
Principal investigator 1 ABBVIE INC. $5,738.24 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202528376
Principal investigator 1 ABBVIE INC. $2,250.00 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202529174
Principal investigator 1 ABBVIE INC. $2,152.65 12/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202529176
Principal investigator 1 ABBVIE INC. $999.00 12/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202526412
Principal investigator 1 ABBVIE INC. $121.50 12/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202526324
Principal investigator 1 ABBVIE INC. $540.00 12/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202526326
Principal investigator 1 SANOFI US SERVICES INC. $12,566.97 11/24/2025 Non-covered Recipient Entity
Equity Medical Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226156646
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 11/24/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156664
Principal investigator 1 ABBVIE INC. $1,093.50 11/20/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202524772
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156605
Principal investigator 1 SANOFI US SERVICES INC. $55,889.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156609
Principal investigator 1 SANOFI US SERVICES INC. $41,990.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156615
Principal investigator 1 SANOFI US SERVICES INC. $2,800.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156620
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156628
Principal investigator 1 SANOFI US SERVICES INC. $3,200.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157119
Principal investigator 1 SANOFI US SERVICES INC. $1,440.00 11/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157142
Principal investigator 1 ABBVIE INC. $843.75 11/13/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202524027
Principal investigator 1 ABBVIE INC. $129.60 11/13/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202524029
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,919.75 11/13/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431868
Principal investigator 1 ABBVIE INC. $199.80 11/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202523811
Principal investigator 1 ABBVIE INC. $270.00 11/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202523813
Principal investigator 1 SANOFI US SERVICES INC. $675.00 11/10/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156589
Principal investigator 1 ABBVIE INC. $56,111.77 11/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202521447
Principal investigator 1 ABBVIE INC. $15,919.05 11/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202521471
Principal investigator 1 SANOFI US SERVICES INC. $4,650.00 11/04/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156634
Principal investigator 1 SANOFI US SERVICES INC. $3,054.00 11/04/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157132
Principal investigator 1 SANOFI US SERVICES INC. $72,265.00 11/04/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157137
Principal investigator 1 ABBVIE INC. $2,606.25 10/30/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202519811
Principal investigator 1 ABBVIE INC. $4,500.00 10/29/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202519621
Principal investigator 1 ABBVIE INC. $4,500.00 10/29/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202519623
Principal investigator 1 ABBVIE INC. $5,811.75 10/28/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202518803
Principal investigator 1 ABBVIE INC. $1,640.25 10/28/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202518805
Principal investigator 1 ABBVIE INC. $756.00 10/28/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202518831
Principal investigator 1 SANOFI US SERVICES INC. $960.00 10/27/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157100
Principal investigator 1 SANOFI US SERVICES INC. $4,701.00 10/27/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226157103
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,619.35 10/23/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431861
Principal investigator 1 ABBVIE INC. $7,275.02 10/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202518153
Principal investigator 1 SANOFI US SERVICES INC. $33,469.00 10/20/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226157091
Principal investigator 1 SANOFI US SERVICES INC. $5,137.00 10/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226157070
Principal investigator 1 SANOFI US SERVICES INC. $1,086.83 10/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226157074
Principal investigator 1 SANOFI US SERVICES INC. $700.00 10/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226157077
Principal investigator 1 SANOFI US SERVICES INC. $12,168.00 10/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226157081
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,160.70 10/09/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431852
Principal investigator 1 Novartis Pharmaceuticals Corporation $57,052.37 10/08/2025 Non-covered Recipient Entity
CAMERON DERMATOLOGY
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190313043
Principal investigator 1 SANOFI US SERVICES INC. $18,280.00 10/06/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226157046
Principal investigator 1 SANOFI US SERVICES INC. $37,753.00 09/29/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157034
Principal investigator 1 ABBVIE INC. $2,300.00 09/25/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202512268
Principal investigator 1 Incyte Corporation $278.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533132
Principal investigator 1 Incyte Corporation $178.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533137
Principal investigator 1 Incyte Corporation $1,308.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533140
Principal investigator 1 Incyte Corporation $442.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533149
Principal investigator 1 Incyte Corporation $248.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533157
Principal investigator 1 Incyte Corporation $530.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533161
Principal investigator 1 Incyte Corporation $54.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533165
Principal investigator 1 Incyte Corporation $128.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533169
Principal investigator 1 Incyte Corporation $45.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533174
Principal investigator 1 Incyte Corporation $1,467.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533179
Principal investigator 1 Incyte Corporation $10,000.00 09/22/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533182
Principal investigator 1 ABBVIE INC. $3,800.00 09/18/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202511376
Principal investigator 1 ABBVIE INC. $1,500.00 09/17/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202511152
Principal investigator 1 SANOFI US SERVICES INC. $49,276.00 09/15/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156998
Principal investigator 1 SANOFI US SERVICES INC. $150.00 09/15/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157013
Principal investigator 1 SANOFI US SERVICES INC. $4,250.00 09/15/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157018
Principal investigator 1 SANOFI US SERVICES INC. $350.00 09/15/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226157024
Principal investigator 1 Incyte Corporation $1,042.49 09/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533186
Principal investigator 1 Incyte Corporation $1,500.00 09/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240533991
Principal investigator 1 Incyte Corporation $2,577.00 09/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240533994
Principal investigator 1 Incyte Corporation $15,000.00 09/12/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240533998
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,959.07 09/11/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431843
Principal investigator 1 ABBVIE INC. $3,000.00 09/09/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202510314
Principal investigator 1 Incyte Corporation $2,828.00 09/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533145
Principal investigator 1 Incyte Corporation $24,300.00 09/05/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533153
Principal investigator 1 ABBVIE INC. $2,500.00 09/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202508874
Principal investigator 1 ABBVIE INC. $5,400.00 09/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202508876
Principal investigator 1 SANOFI US SERVICES INC. $1,288.00 09/03/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226157001
Principal investigator 1 ABBVIE INC. $2,000.00 09/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202506917
Principal investigator 1 ABBVIE INC. $2,300.00 08/28/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202506397
Principal investigator 1 ABBVIE INC. $300.00 08/28/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202506399
Principal investigator 1 ABBVIE INC. $5,000.00 08/27/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202505999
Principal investigator 1 ABBVIE INC. $5,000.00 08/27/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202506005
Principal investigator 1 SANOFI US SERVICES INC. $47,436.00 08/25/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156993
Principal investigator 1 SANOFI US SERVICES INC. $38,578.00 08/25/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226157028
Principal investigator 1 SANOFI US SERVICES INC. $900.00 08/18/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156957
Principal investigator 1 SANOFI US SERVICES INC. $13,370.00 08/18/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156959
Principal investigator 1 SANOFI US SERVICES INC. $5,600.00 08/18/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156976
Principal investigator 1 SANOFI US SERVICES INC. $6,561.00 08/18/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156980
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 08/18/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156982
Principal investigator 1 SANOFI US SERVICES INC. $3,600.00 08/11/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156962
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 08/11/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156965
Principal investigator 1 SANOFI US SERVICES INC. $5,187.00 08/11/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156968
Principal investigator 1 ABBVIE INC. $5,778.38 08/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202503087
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,505.36 08/06/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431831
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,645.06 08/06/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431833
Principal investigator 1 ABBVIE INC. $6,225.00 07/30/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202500524
Principal investigator 1 Eli Lilly and Company $3,317.45 07/28/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187879039
Principal investigator 1 SANOFI US SERVICES INC. $7,896.08 07/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156936
Principal investigator 1 SANOFI US SERVICES INC. $17,400.00 07/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156939
Principal investigator 1 SANOFI US SERVICES INC. $1,950.00 07/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156948
Principal investigator 1 SANOFI US SERVICES INC. $24,862.65 07/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156953
Principal investigator 1 Incyte Corporation $125.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533191
Principal investigator 1 Incyte Corporation $912.00 07/23/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533193
Principal investigator 1 SANOFI US SERVICES INC. $48,020.00 07/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156842
Principal investigator 1 SANOFI US SERVICES INC. $32,184.00 07/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156847
Principal investigator 1 SANOFI US SERVICES INC. $176,689.00 07/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156854
Principal investigator 1 ABBVIE INC. $3,791.47 07/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202497382
Principal investigator 1 ABBVIE INC. $4,996.03 07/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497384
Principal investigator 1 ABBVIE INC. $4,710.90 07/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202496219
Principal investigator 1 ABBVIE INC. $4,956.00 07/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202496221
Principal investigator 1 ABBVIE INC. $2,916.28 07/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202496225
Principal investigator 1 SANOFI US SERVICES INC. $5,187.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156837
Principal investigator 1 SANOFI US SERVICES INC. $6,000.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156860
Principal investigator 1 SANOFI US SERVICES INC. $750.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156864
Principal investigator 1 SANOFI US SERVICES INC. $750.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156868
Principal investigator 1 SANOFI US SERVICES INC. $375.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156872
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156879
Principal investigator 1 SANOFI US SERVICES INC. $13,000.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156883
Principal investigator 1 SANOFI US SERVICES INC. $26,370.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156887
Principal investigator 1 SANOFI US SERVICES INC. $1,375.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156889
Principal investigator 1 SANOFI US SERVICES INC. $6,448.30 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156892
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156901
Principal investigator 1 SANOFI US SERVICES INC. $7,897.03 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156904
Principal investigator 1 SANOFI US SERVICES INC. $20,085.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156911
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156915
Principal investigator 1 SANOFI US SERVICES INC. $186.03 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156919
Principal investigator 1 SANOFI US SERVICES INC. $9,700.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156925
Principal investigator 1 SANOFI US SERVICES INC. $1,950.00 07/02/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156929
Principal investigator 1 SANOFI US SERVICES INC. $61,982.00 06/16/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156813
Principal investigator 1 SANOFI US SERVICES INC. $18,500.00 06/16/2025 Non-covered Recipient Entity
Equity Medical Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226156816
Principal investigator 1 Incyte Corporation $2,874.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533107
Principal investigator 1 Incyte Corporation $2,824.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533111
Principal investigator 1 Incyte Corporation $440.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533115
Principal investigator 1 Incyte Corporation $1,875.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533119
Principal investigator 1 Incyte Corporation $2,894.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533123
Principal investigator 1 Incyte Corporation $1,289.00 06/04/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533128
Principal investigator 1 ABBVIE INC. $9,823.50 06/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202488913
Principal investigator 1 ABBVIE INC. $17,006.40 06/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202488915
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $12,500.00 05/28/2025 Non-covered Recipient Entity
Equity Medical LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431822
Principal investigator 1 SANOFI US SERVICES INC. $8,256.00 05/27/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156809
Principal investigator 1 Eli Lilly and Company $13,612.00 05/20/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880593
Principal investigator 1 SANOFI US SERVICES INC. $14,045.00 05/19/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156820
Principal investigator 1 SANOFI US SERVICES INC. $16,638.00 05/12/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156805
Principal investigator 1 ABBVIE INC. $11,875.03 05/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202482563
Principal investigator 1 ABBVIE INC. $18,375.00 05/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482565
Principal investigator 1 ABBVIE INC. $4,986.30 05/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202482567
Principal investigator 1 SANOFI US SERVICES INC. $42,050.50 05/05/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156792
Principal investigator 1 Incyte Corporation $2.04 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533907
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533911
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533915
Principal investigator 1 Incyte Corporation $58.78 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533918
Principal investigator 1 Incyte Corporation $33.96 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533924
Principal investigator 1 Incyte Corporation $6.88 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533928
Principal investigator 1 Incyte Corporation $2.94 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533932
Principal investigator 1 Incyte Corporation $3.92 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533936
Principal investigator 1 Incyte Corporation $0.68 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533940
Principal investigator 1 Incyte Corporation $89.31 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533944
Principal investigator 1 Incyte Corporation $20.65 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533948
Principal investigator 1 Incyte Corporation $0.28 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533952
Principal investigator 1 Incyte Corporation $1.25 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533956
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533959
Principal investigator 1 Incyte Corporation $58.78 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533964
Principal investigator 1 Incyte Corporation $120.06 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533967
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533971
Principal investigator 1 Incyte Corporation $29.52 05/02/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533975
Principal investigator 1 SANOFI US SERVICES INC. $70,365.00 04/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156780
Principal investigator 1 SANOFI US SERVICES INC. $16,900.00 04/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156789
Principal investigator 1 SANOFI US SERVICES INC. $1,375.00 04/28/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156797
Principal investigator 1 SANOFI US SERVICES INC. $7,248.00 04/14/2025 Non-covered Recipient Entity
Dermatology Research Associates
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226098229
Principal investigator 1 SANOFI US SERVICES INC. $22,995.00 04/14/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226156777
Principal investigator 1 SANOFI US SERVICES INC. $9,054.00 04/14/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156785
Principal investigator 1 ABBVIE INC. $14,819.25 04/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202471915
Principal investigator 1 ABBVIE INC. $10,880.55 04/03/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202471919
Principal investigator 1 SANOFI US SERVICES INC. $127,349.00 03/24/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226156762
Principal investigator 1 SANOFI US SERVICES INC. $26,286.00 03/24/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156768
Principal investigator 1 SANOFI US SERVICES INC. $51,313.90 03/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156746
Principal investigator 1 SANOFI US SERVICES INC. $19,568.00 03/17/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226157152
Principal investigator 1 ABBVIE INC. $11,409.00 03/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202461543
Principal investigator 1 ABBVIE INC. $10,265.70 03/07/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202461547
Principal investigator 1 SANOFI US SERVICES INC. $16,100.00 03/04/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226157157
Principal investigator 1 SANOFI US SERVICES INC. $67,581.90 02/24/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156749
Principal investigator 1 ABBVIE INC. $2,079.75 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202447570
Principal investigator 1 ABBVIE INC. $6,726.45 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202447628
Principal investigator 1 Incyte Corporation $9.45 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533754
Principal investigator 1 Incyte Corporation $6.88 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533758
Principal investigator 1 Incyte Corporation $190.62 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533762
Principal investigator 1 Incyte Corporation $27.75 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533766
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533770
Principal investigator 1 Incyte Corporation $12.20 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533774
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533778
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533782
Principal investigator 1 Incyte Corporation $6.25 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533786
Principal investigator 1 Incyte Corporation $103.25 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533790
Principal investigator 1 Incyte Corporation $1.40 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533794
Principal investigator 1 Incyte Corporation $2.04 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533797
Principal investigator 1 Incyte Corporation $0.44 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533801
Principal investigator 1 Incyte Corporation $3.32 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533805
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533809
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533813
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533817
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533822
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533826
Principal investigator 1 Incyte Corporation $33.96 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533830
Principal investigator 1 Incyte Corporation $1.02 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533834
Principal investigator 1 Incyte Corporation $104.56 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533837
Principal investigator 1 Incyte Corporation $76.92 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533842
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533846
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533850
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533854
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533858
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533862
Principal investigator 1 Incyte Corporation $24.36 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533866
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533870
Principal investigator 1 Incyte Corporation $13.60 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533874
Principal investigator 1 Incyte Corporation $114.50 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533877
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533882
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533886
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533890
Principal investigator 1 Incyte Corporation $9.72 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533894
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533898
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
EQUITY MEDICAL, LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533903
Principal investigator 1 SANOFI US SERVICES INC. $4,658.00 02/04/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226157161
Principal investigator 1 Novartis Pharmaceuticals Corporation $201,956.86 02/01/2025 Non-covered Recipient Entity
CAMERON DERMATOLOGY
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190312493
Recipient Eli Lilly and Company $3,083.63 01/27/2025 Covered Recipient Physician EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187871895
Principal investigator 1 Eli Lilly and Company $332,141.00 01/21/2025 Non-covered Recipient Entity
EQUITY MEDICAL LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187882018
Principal investigator 1 SANOFI US SERVICES INC. $43,779.10 01/21/2025 Non-covered Recipient Entity
Equity Medical Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226156751
Principal investigator 1 SANOFI US SERVICES INC. $21,036.00 01/13/2025 Non-covered Recipient Entity
Equity Medical Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226156772
Principal investigator 1 Incyte Corporation $2,874.00 01/08/2025 Non-covered Recipient Entity
EQUITY MEDICAL
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240533103